Kemik, OzgurSumer, AzizKemik, Ahu SarbayItik, VeyisDulger, Ahmet CumhurPurisa, SevimTuzun, Sefa2025-05-102025-05-1020101477-781910.1186/1477-7819-8-832-s2.0-77957340031https://doi.org/10.1186/1477-7819-8-83https://hdl.handle.net/20.500.14720/1680Kemik, Ozgur/0000-0002-4612-1428Background: The incidence of hepatocellular cancer in complicated alcoholic and non-alcoholic fatty liver diseases is on the rise in western countries as well in our country. Vascular adhesion protein-1 (VAP-1) levels have been presented as new marker. In our study protocol, we assessed the value of this serum protein, as a newly postulant biomarker for hepatocellular cancer in patients with a history of alcoholic and non-alcoholic fatty liver diseases. Methods: Pre-operative serum samples from 55 patients with hepatocellular cancer with a history of alcoholic and non-alcoholic fatty liver diseases and patients with cirrhosis were assessed by a quantitative sandwich ELISA using anti-VAP-1 mAbs. This technique is used to determine the levels of soluble VAP-1 (sVAP-1) in the serum. Results: sVAP-1 levels were evaluated in patients with hepatocellular cancer and liver cirrhosis. There was a significant difference in mean VAP-1 levels between groups. Serum VAP-1 levels were found higher in patients with hepatocellular cancer. Conclusion: These findings indicate that the serum level of sVAP-1 might be a beneficial marker of disease activity in chronic liver diseases.eninfo:eu-repo/semantics/openAccessHuman Vascular Adhesion Protein-1 (vap-1): Serum Levels for Hepatocellular Carcinoma in Non-Alcoholic and Alcoholic Fatty Liver DiseaseArticle8Q1Q220849600WOS:000282612500001